Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma

Cancer

Volumn 89, Issue 8, 2000, Pages 1706-1713

  Feliu, J ^a,h   Lopez Alvarez M P ^b   Jaraiz, M A ^c   Constenla, M ^d   Vicent, J M ^e   Belon J ^f   Lopez Gomez L ^g   De Castro, J ^a   Dorta, J ^b   Gonzalez Baron M ^a  

^a Departments of Medical Oncology   (Spain)

^b Services of Medical Oncology   (Spain)

^c Service of Medical Oncology   (Spain)

^d Medical Oncology Service   (Spain)

^e Hospital General Universitario   (Spain)

^f Services of Medical Oncology   (Spain)

^g Service of Medical Oncology H Virgen de la Salud   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Chemotherapy; Clinical benefit; Gemcitabine; Leucovorin; Pancreas; Pancreatic carcinoma; UFT

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; UFT;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMAN; MALE; MIDDLE AGE; NEOPLASM METASTASIS; PAIN; PANCREATIC NEOPLASMS; TEGAFUR; URACIL;

EID: 0034667867     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001015)89:8<1706::AID-CNCR9>3.0.CO;2-I     Document Type: Article

References (47)

1. Cancer statistics
2. The role of the chemotherapy in the management of gastric and pancreatic carcinomas
3. Practical recommendations for the management of adenocarcinoma of the pancreas
4. Chemotherapy of adenocarcinoma of the pancreas
5. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
6. Chemotherapy prolongs survival in inoperable pancreatic carcinoma
7. Cellular basis for the inefficacy of 5-FU in human colon carcinoma
8. Continuous 5-fluorouracil (5-FU) infusion in carcinoma of the pancreas: A phase II study
9. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma
10. Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic or pancreatic carcinoma
11. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas. Results of a phase II trial
12. A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus matched tumor registry control population
13. Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2a: Results of a phase II trial
14. Phase II trial of gemcitabine (2', 2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
15. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
16. Ex vivo ATP tumor testing gemcitabine for combination chemotherapy and biochemical modulation
17. Phase II study of docetaxel as first line chemotherapy in metastatic adenocarcinoma of the pancreas
18. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: A Southwest Oncology Group Study
19. Phase II trial of CPT11 in patients with advanced pancreatic cancer, an EORTC early clinical trial group study
20. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas
21. Effect of coadministration of uracil or cytosine on the antitumour activity of clinical doses of (2-tetrahydrofuryl)-5-fluorouracil and level of 5 fluorouracil in rodents
22. Effect of uracil on metabolism of 5-fluorouracil in vitro
23. Determination of 5-fluorouracil levels in tumor blood and other tissues
24. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-florouracil
25. Phase I study of UFT plus leucovorin in advanced colorectal cancer: A double modulation proposal
26. Effect of excess folates and deoxynosine on the activity and site of action of 5-fluorouracil
27. Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin in combination with fluorouracil in patients with advanced colorectal carcinoma
28. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study
29. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group
30. Reporting results of cancer treatment
31. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
32. One-sample multiple testing procedure for phase II clinical trials
33. Should further studies of chemotherapy be carried out in pancreatic cancer?
34. No standard treatment is available for advanced pancreatic cancer
35. Saturation of 2',2',-difluorodeoxycitidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
36. Randomized phase II trial of dose intense gemcitabine by standard infusion vs fixed dose rate in metastatic pancreatic adenocarcinoma
37. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model
38. Randomized trial of gemcitabine (GEM) alone or with cisplatin (CDDP) in treatment of advanced pancreatic cancer (APC): A phase II multicenter study of the Southern Italy Oncology Group [abstract 961J
39. Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer. Final results of a phase II study
40. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer
41. Action of 2',2'-difluoro-2'-deoxycytidine on DNA synthesis
42. Gemcitabine (GEM) and 5-fluorouracil (5FU) in advanced pancreatic cancer: A GISCARD phase II study
43. Phase II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer
44. Multicenter phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5FU bolus and infusion, and gemcitabine (FOLFUGEM regimen)
45. Report on nationwide pooled data and cohort investigation in UFT phase II study
46. UFT plus leucovorin in advanced hepatobiliary tumors and pancreatic adenocarcinomas. An ongoing phase II study
47. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer